消息面上，12月13日，全国医疗保障工作会议在北京召开。会上提到，要积极适应人口发展战略，推动 生育保险和长期护理保险发展。其中包括，合理提升产前检查医疗费用保障水平，力争全国基本实现政 策范围内分娩个人"无自付"。会议提出，2025年，31个省（区、市）及新疆生产建设兵团均已将符合条 件的辅助生殖项目纳入医保，7个省份实现政策范围内住院分娩医疗费用全额保障，95%的统筹区将生 育津贴直接发放给参保人。 智通财经APP获悉，锦欣生殖(01951)涨超3%，截至发稿，涨3.59%，报2.6港元，成交额4539.81万港 元。 本月初，锦欣生殖发布公告称，董事会已议决利用购回授权，以不时在公开市场上按不少于1亿港元的 总价格购回股份。据锦欣生殖投资者关系消息，上周公司回购股份2322.4万股，耗资5771.7万港币。截 止目前，本月已完成回购3094.6万股，总金额7751.5万港币。公司表示未来将继续专注提升经营业绩， 推动公司内在价值增长，致力为股东创造可持续的回报。 ...

恐慌情绪蔓延！上周五美股大跌；今日将公布社零等重磅经济数据。港股三大指数大幅低开，恒指跌 1%，国指跌1.09%，恒生科技指数跌1.34%。权重科技股集体下跌，其中百度跌超3%，阿里巴巴、腾 讯、小米均有跌幅；内房股、生物医药股、有色金属股齐跌。另外，三胎概念股、光伏股多数上涨，明 星股锦欣生殖涨约3%。(格隆汇) ...

Summary of Key Points Core Viewpoint - The article discusses the stock buyback activities of various companies, highlighting the amounts repurchased and their significance in terms of total shares outstanding. Group 1: Major Buybacks - Tencent Holdings (00700) had the largest buyback, repurchasing 1.044 million shares for a total of 636 million [1][2] - China Merchants Industry Holdings (01919) repurchased 4.461 million shares for 60.86 million, representing 2.986% of its total shares [2] - Geely Automobile (00175) bought back 1.362 million shares for 23.92 million, which is 0.078% of its total shares [2] Group 2: Notable Buyback Activities - China Feihe (06186) repurchased 5.655 million shares for 23.18 million, accounting for 2.605% of its total shares [2] - Yum China (09987) conducted two buybacks totaling 58,000 shares for 21.67 million, representing 4.750% of its total shares [2] - Kweichow Moutai (01951) repurchased 772,200 shares for 19.35 million, which is 0.280% of its total shares [2] Group 3: Other Companies Involved - Vitasoy International (00345) repurchased 2,000 shares for 13,300, which is 2.209% of its total shares [3] - Yanzhiyu (01497) bought back 200,000 shares for 1.39 million, representing 0.786% of its total shares [3] - Weigao Group (01066) repurchased 120,000 shares for 631,000, which is 5.179% of its total shares [3]

Core Viewpoint - Jinxin Reproductive Medicine (01951.HK) has conducted share buybacks for six consecutive days, totaling 30.946 million shares repurchased, amounting to HKD 77.515 million [1] Buyback Details - On December 12, the company repurchased 7.722 million shares at prices ranging from HKD 2.460 to HKD 2.530, with a total buyback amount of HKD 19.352 million [1] - The stock closed at HKD 2.510 on the same day, reflecting a 3.29% increase, with total trading volume of HKD 65.944 million [1] - Cumulatively, since December 5, the stock has increased by 0.40% during the buyback period [1] Buyback Summary Table - The buyback details are as follows: - December 12: 772.20 thousand shares, max price HKD 2.530, min price HKD 2.460, total amount HKD 19.352 million - December 11: 384.60 thousand shares, max price HKD 2.530, min price HKD 2.430, total amount HKD 9.542 million - December 10: 192.55 thousand shares, max price HKD 2.490, min price HKD 2.430, total amount HKD 4.766 million - December 9: 380.20 thousand shares, max price HKD 2.500, min price HKD 2.400, total amount HKD 9.208 million - December 8: 592.85 thousand shares, max price HKD 2.580, min price HKD 2.470, total amount HKD 14.849 million - December 5: 772.20 thousand shares, max price HKD 2.580, min price HKD 2.550, total amount HKD 19.798 million [1]

Group 1 - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan, committing to repurchase 7.722 million shares at a total cost of HKD 19.3521 million [1]

Core Viewpoint - Jinxin Reproductive (01951.HK) announced a share buyback on December 12, spending HKD 19.352 million to repurchase 7.722 million shares [1] Group 1 - The company executed a buyback of shares, indicating a strategic move to enhance shareholder value [1] - The total expenditure for the buyback was HKD 19.352 million, reflecting the company's commitment to returning capital to shareholders [1] - A total of 7.722 million shares were repurchased, which may influence the stock's liquidity and market perception [1]

公司名稱： 錦欣生殖醫療集團有限公司 呈交日期： 2025年12月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 ...

Group 1 - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan on December 11, 2025, involving an expenditure of HKD 9.5421 million to repurchase 3.846 million shares [1]

Group 1 - The company, Jinxin Reproductive Medicine (01951.HK), announced a share buyback on December 11, 2023, spending HKD 9.542 million to repurchase 3.846 million shares [1] - The buyback price ranged from HKD 2.43 to HKD 2.53 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 第 2 頁 共 7 頁 v 1.3.0 公司名稱： 錦欣生殖醫療集團有限公司 呈交日期： 2025年12月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事 ...